Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study

European Neuropsychopharmacology

Volumn 22, Issue 2, 2012, Pages 132-136

  Fabrazzo, Michele ^a   Perris, Francesco ^a   Monteleone, Palmiero ^a   Esposito, Giuseppina ^a   Catapano, Francesco ^a   Maj, Mario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aripiprazole; Augmentation; Clomipramine; Depression

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; OPEN STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855195037     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.06.006     Document Type: Article

References (31)

1. Ananth J. Treatment-resistant depression. Psychother. Psychosom. 1998, 67:61-70.
2. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68:843-853.
3. Bowles T.M., Levin G.M. Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother. 2003, 37:687-694.
4. Cuffel B.J., Azocar F., Tomlin M., Greenfield S.F., Busch A.B., Croghan T.W. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J. Clin. Psychiatry 2003, 64:397-402.
5. da Rocha F.F., Correa H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1550-1551.
6. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 53:649-659.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician version 1997, American Psychiatric Press, Washington, USA.
8. Friedman S., Abdallah T.A., Oumaya M., Rouillon F., Guelfi J.D. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J. Clin. Psychiatry 2007, 68:972-973.
9. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
10. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004, 483:45-53.
11. Kemp D.E., Gilmer W.S., Fleck J., Straus J.L., Dago P.L., Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog. in Neuropsychopharmacol. Biomed. Psychiatry 2007, 31:574-577.
12. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. J. Clin. Psychopharmacol. 2008, 28:156-165.
13. Marescaux P., Belan E., Houdret N., Goudemand M., Lhermitte M. Simultaneous determination of clomipramine and its demethylated metabolite in plasma and erythrocytes by high-performance liquid chromatography. J. Liq. Chromatogr. Relat. Technol. 1994, 17:2171-2177.
14. Nelson J.C., Price L.H., Jatlow P.I. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am. J. Psychiatry 1986, 143:1151-1154.
15. Pae C.U., Patkar A.A., Jun T.Y., Lee C., Masand P.S., Paik I.H. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress. Anxiety 2007, 24:522-526.
16. Pae C.U., Serretti A., Patkar A.A., Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008, 22:367-388.
17. Papakostas G.I., Shelton R.C., Smith J., Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry 2007, 68:826-831.
18. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
19. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M., STAR*D Study Team Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:1231-1242.
20. Rutherford B., Sneed J., Miyazaki M., Eisenstadt R., Devanand D., Sackeim H., Roose S. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry 2007, 22:986-991.
21. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
22. Sheffrin M., Driscoll H.C., Lenze E.J., Mulsant B.H., Pollock B.G., Miller M.D., Butters M.A., Dew M.A., Reynolds C.F. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J. Clin. Psychiatry 2009, 70:208-213.
23. Shelton R.C., Papakostas G.I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr. Scand. 2008, 117:253-259.
24. Spina E., de Leon J. Metabolic interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. 2007, 100:4-22.
25. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(supp 13):23-29.
26. Trivedi M.H., Rush A.J., Crismon M.L., Kashner T.M., Toprac M.G., Carmody T.J., Key T., Biggs M.M., Shores-Wilson K., Witte B., Suppes T., Miller A.L., Altshuler K.Z., Shon S.P. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch. Gen. Psychiatry 2004, 61:669-680.
27. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., Ritz L., Nierenberg A.A., Lebowitz B.D., Biggs M.M., Luther J.F., Shores-Wilson K., Rush A.J., STAR*D Study Team Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:1243-1252.
28. Urichuk L., Prior T.I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008, 9:410-418.
29. Von Moltke L.L., Greenblatt D.J., Harmatz J.S., Shader R.I. Cytochromes in psychopharmacology. J. Clin. Psychopharmacol. 1994, 14:1-4.
30. Weber J., Lyseng-Williamson K.A., Scott L.J. Aripiprazole: in major depressive disorder. CNS Drugs 2008, 22:807-813.
31. Yang H., Chuzi S., Sinicropi-Yao L., Johnson D., Chen Y., Clain A., Baer L., McGrath P.J., Stewart J.W., Fava M., Papakostas G.I. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260:145-150.